None listed
Conditions
Brief summary
The Airvo device has been developed to deliver oxygen to patients. It is not known, however, how this method of delivery influences blood carbon dioxide levels. In some patients there is a chance of oxygen causing hypercapnia (elevation in blood carbon dioxide), this includes those with chronic obstructive pulmonary disease (COPD). To understand clinical utility and safety, it is crucial to determine how supplementary oxygen administered by the Airvo device influences carbon dioxide and compare this with similar oxygen concentrations delivered by nasal cannulae.
Interventions
Oxygen administered via the Airvo device titrated to the patient's oxygen saturation at the start of the study (as measured via a TOSCA) for 30 minutes. Note this is to be followed by a 15 minute washout/observation period during which the patient is placed on the oxygen flow delivered at the start of the study.
Sponsors
Medical Research Institute of New Zealand
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Investigator)
Eligibility
Sex/Gender
All
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Twenty four participants with COPD will be recruited from Wellington Regional Hospital during an acute exacerbation. To be eligible participants will be receiving oxygen via standard nasal prongs, without any non invasive assisted ventilation at recruitment.
Exclusion criteria
1. Age under 16 years 2. Any other condition which, at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or the study results.
Outcome results
None listed